METEORA-II: metronomic VEX versus paclitaxel in ER+/HER2- metastatic breast cancer

Unanswered questions in the METEORA-II trialПодробнее

Dr. Sara Tolaney on Adjuvant T-DM1 Vs Paclitaxel and Trastuzumab for Stage I HER2+ Breast CancerПодробнее

APT: adjuvant paclitaxel and trastuzumab for node-negative, HER2+ breast cancerПодробнее

Treating metastatic breast cancer with metronomic VEX in the METEORA-II trialПодробнее

Study comparing margetuximab combinations to trastuzumab combinations in HER2-positive breast cancerПодробнее

ER+/HER2+ Metastatic Breast CancerПодробнее

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trialПодробнее

Metastatic HER2+ Breast CancerПодробнее

Using metronomic chemotherapy as a second-line treatment in head and neck cancerПодробнее

Survival in premenopausal HR+/HER2- breast cancer with micro-metastasis and 21-gene scoreПодробнее

SURPASS: evaluating the next-generation of SPEAR T-cell therapyПодробнее

ICON: chemotherapy combined with ipilimumab and nivolumab in metastatic HR+ breast cancerПодробнее

The best sequence of endocrine treatment in metastatic luminal Breast Cancer:solving the puzzleПодробнее

ESMO22: Breast cancer research by Sara Tolaney, MD (TROPiCS) | Dana-Farber Cancer InstituteПодробнее

ICAHO19 - Breast cancer session: Sequencing therapies in metastatic breast cancerПодробнее

Optimizing Chemotherapy for Metastatic Breast CancerПодробнее

Nab-paclitaxel-based induction therapy, chemotherapy and re-irradiation for head and neck cancerПодробнее

EMERALD: elacestrant vs. SOC for patients with ER+ HER2- metastatic breast cancerПодробнее

Palliative weekly Paclitaxel in advanced, recurrent, and metastatic esophageal cancerПодробнее